Comparing Innovation Spending: United Therapeutics Corporation and Amphastar Pharmaceuticals, Inc.

R&D Spending: United Therapeutics vs. Amphastar

__timestampAmphastar Pharmaceuticals, Inc.United Therapeutics Corporation
Wednesday, January 1, 201428427000242549000
Thursday, January 1, 201537065000245098000
Friday, January 1, 201641199000147600000
Sunday, January 1, 201743415000264600000
Monday, January 1, 201857564000357900000
Tuesday, January 1, 2019688530001182600000
Wednesday, January 1, 202067229000357700000
Friday, January 1, 202160932000540100000
Saturday, January 1, 202274771000322900000
Sunday, January 1, 202373741000408000000
Loading chart...

Igniting the spark of knowledge

Innovation Spending: A Tale of Two Companies

In the competitive landscape of pharmaceuticals, innovation is key. United Therapeutics Corporation and Amphastar Pharmaceuticals, Inc. have shown distinct strategies in their research and development (R&D) investments over the past decade. From 2014 to 2023, United Therapeutics consistently outpaced Amphastar, with R&D expenses peaking in 2019 at nearly four times Amphastar's highest spending year. This strategic focus on innovation has allowed United Therapeutics to maintain a robust pipeline, while Amphastar's more conservative approach reflects a different business model.

A Decade of Change

United Therapeutics' R&D spending surged by approximately 68% from 2014 to 2023, highlighting their commitment to groundbreaking therapies. In contrast, Amphastar's R&D expenses grew by about 160%, albeit from a smaller base, indicating a gradual shift towards more innovation. This divergence in spending underscores the varied paths companies take in the quest for pharmaceutical breakthroughs.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025